Get the Stockscreener App
25.89
1.56%
-0.41
After Hours:
26.29
0.40
+1.54%
Hemab Therapeutics Holdings Inc stock is traded at $25.89, with a volume of 135.23K.
It is down -1.56% in the last 24 hours and up +0.00% over the past month.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
See More
Previous Close:
$26.30
Open:
$26.3
24h Volume:
135.23K
Relative Volume:
2.47
Market Cap:
$1.21B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-7.77%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$25.20
$27.04
1-Week Range:
$24.21
$27.94
52-Week Range:
$23.00
$32.00
Hemab Therapeutics Holdings Inc Stock (COAG) Company Profile
Name
Hemab Therapeutics Holdings Inc
Sector
Industry
Phone
45 2138 7627
Address
101 MAIN STREET, CAMBRIDGE
Compare COAG vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COAG
Hemab Therapeutics Holdings Inc
|
25.89 | 1.23B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hemab Therapeutics Holdings Inc Stock (COAG) Latest News
ETFs Investing in Hemab Therapeutics Holdings, Inc. Stocks - TradingView
Top Hemab Therapeutics (COAG) Competitors 2026 - MarketBeat
Hemab Therapeutics (COAG) Earnings Date and Reports 2026 - MarketBeat
COAG Technical Analysis | Trend, Signals & Chart Patterns | HEMAB THERAPEUTICS HOLDINGS (NASDAQ:COAG) - ChartMill
Earnings Scheduled For May 21, 2026 - Sahm
Novo-backed biotech Hemab raises $301.5 million in upsized IPO - MSN
COAG SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Hemab Therapeutics Holdings, Inc. Q1 2026: Net loss $(22.7)M, EPS $(23.98) — 10-Q Summary - TradingView
Hemab Therapeutics Reports Q1 2026 Financial Results, Completes $346.7M IPO and Advances Breakthrough Therapy Sutacimig for Rare Bleeding Disorders - Minichart
Earnings Flash (COAG) Hemab Therapeutics Posts Q1 Net Loss $23.98 a Share - marketscreener.com
Hemab Therapeutics reports Q1 2026 net loss $22.7M, cash $163.5M; completed $346.7M IPO - TradingView
COAG: IPO raised $346.7M, advancing late-stage trials for rare bleeding disorder therapies - TradingView
Hemab Therapeutics (COAG) Q1 2026 loss, $346.7M IPO and FDA breakthrough nod - Stock Titan
FDA grants Hemab breakthrough tag on rare bleed drug as $346.7M IPO closes - Stock Titan
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) AI-Powered Stock Analysis - Meyka
Hemab Therapeutics Hldgs (COAG) Stock Analysis Report | Financials & Insights - Benzinga España
Why Is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock Up Today? - Meyka
Why Is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock Down Today? - Meyka
Seaport, Hemab price upsized IPOs, eyeing $550M in proceeds - MSN
COAG SEC FilingsHEMAB THERAPEUTICS HOLDINGS 10-K, 10-Q, 8-K Forms - Stock Titan
Hemab Therapeutics Holdings Earnings Date, Reports & Earnings Call - Moomoo
Hemab Therapeutics Holdings (COAG) Stock Forecast & Analyst Ratings - Moomoo
Hemab Therapeutics Holdings Inc. (COAG) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Hemab, Seaport surge as clinical-stage biotechs make trading debuts - MSN
AI DEN-MAB LLC discloses 4,876,344 Hemab Therapeutics (COAG) shares - Stock Titan
Hemab Therapeutics (COAG) Stock Trends and Sentiment 2026 - MarketBeat
Hemab Therapeutics Closes Upsized Initial Public Offering on Nasdaq - Global Legal Chronicle
RA Capital reveals 16.6% stake in Hemab Therapeutics (NASDAQ: COAG) - Stock Titan
RA Capital funds boost Hemab Therapeutics (COAG) stake with open-market buys - Stock Titan
Hemab Therapeutics (COAG) Insider Trading Activity 2026 - MarketBeat
Access Industries (NASDAQ: COAG) discloses 10.4% Hemab Therapeutics ownership stake - Stock Titan
Board member Laura Tadvalkar resigns from Hemab Therapeutics (NASDAQ: COAG) board - Stock Titan
Hemab Therapeutics Holdings, Inc. Announces Resignation of Laura Tadvalkar as Member of the Board of Directors , Effective on May 8, 2026 - marketscreener.com
Hemab Therapeutics (COAG) 10K Form and Latest SEC Filings 2026 - MarketBeat
Deep Track (COAG) reports 8.15% ownership in Hemab Therapeutics - Stock Titan
Novo-backed biotech Hemab seeks to raise $212 million in US IPO - MSN
Biotech firm Odyssey raises $279 million in upsized US IPO - marketscreener.com
Hemab Therapeutics Holdings Inc Stock (COAG) Financials Data
There is no financial data for Hemab Therapeutics Holdings Inc (COAG). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):